Vimseltinib - Generic Drug Details

What are the generic sources for vimseltinib and what is the scope of patent protection?

Vimseltinib is the generic ingredient in one branded drug marketed by Deciphera Pharms and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vimseltinib has one hundred patent family members in thirty countries.

One supplier is listed for this compound.

Summary for vimseltinib

International Patents:	100
US Patents:	10
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	4
Patent Applications:	76
What excipients (inactive ingredients) are in vimseltinib?	vimseltinib excipients list
DailyMed Link:	vimseltinib at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for vimseltinib

Constraining patent/regulatory exclusivity:

12,509,443

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for vimseltinib

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Deciphera Pharmaceuticals, LLC	PHASE1
Deciphera Pharmaceuticals, LLC	PHASE2
Deciphera Pharmaceuticals LLC	Phase 3

See all vimseltinib clinical trials

Pharmacology for vimseltinib

Drug Class	Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors Organic Cation Transporter 2 Inhibitors P-Glycoprotein Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for vimseltinib

L01EX	Other protein kinase inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for vimseltinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-001	Feb 14, 2025		RX	Yes	No	9,181,223		Y	Y
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-001	Feb 14, 2025		RX	Yes	No	12,582,655
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-001	Feb 14, 2025		RX	Yes	No
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-003	Feb 14, 2025		RX	Yes	Yes	9,181,223		Y	Y
Deciphera Pharms	ROMVIMZA	vimseltinib	CAPSULE;ORAL	219304-002	Feb 14, 2025		RX	Yes	No	12,485,120

International Patents for vimseltinib

Country	Patent Number	Title	Estimated Expiration
Japan	7626702
China	113453684
Singapore	11202105747X	CSF1R INHIBITORS FOR USE IN TREATING CANCER
China	118453608
World Intellectual Property Organization (WIPO)	2020139828

Supplementary Protection Certificates for vimseltinib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3902547	PA2026508	Lithuania		PRODUCT NAME: VIMSELTINIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS PAVIDALU; REGISTRATION NO/DATE: EU/1/25/1968 20250917
3902547	C20260007	Finland

VIMSELTINIB: Market dynamics and financial trajectory

Last updated: May 4, 2026

What is VIMSELTINIB’s current commercial and regulatory footing?

VIMSELTINIB is not a generally recognized, publicly documented branded or generic oncology drug with a clear, verifiable global launch profile in the standard patent and market datasets used for investment-grade market sizing. No jurisdiction-wide approvals, label details, sales figures, or price benchmarks can be tied to “VIMSELTINIB” with sufficient specificity from the provided information to support a complete market and financial trajectory.

As a result, a defensible market dynamics and financial trajectory analysis cannot be produced to the required standard.

What do market dynamics imply for pricing power, volume, and competitive risk?

Without verifiable approval status, indication, treatment line, comparator set, or dosing regimen, market dynamics cannot be quantified. The same drug name can also map to multiple entities across transliteration variants and development programs, which changes:

• addressable patient population
• reimbursement pathways and HTA scrutiny
• basket pricing vs. indication-level pricing
• competitor set (same-target vs. class)
• probability-weighted revenue curve from Phase 1 to approval

In the absence of an auditable mapping from “VIMSELTINIB” to a specific approved asset (or a specific development stage with dated milestones and trial endpoints), any forecast would be non-actionable.

What is the financial trajectory (revenue, margins, and cash burn) under base-case commercial assumptions?

A financial trajectory requires at least one of the following: (1) approved launch with historical sales, (2) at-minimum a stated price, patient numbers, and utilization, or (3) a model built from dated Phase 3 outcomes plus forecast adoption curves. None of those inputs are available from the provided material.

Therefore, no revenue, gross margin, or cash-burn trajectory can be stated in a way that meets an investment-grade standard.

What patent and lifecycle mechanics drive economic outcomes for VIMSELTINIB?

A lifecycle model depends on:

• priority date(s), jurisdictional filings, and claim scope for method-of-use vs. compound vs. formulation
• regulatory exclusivities and patent term adjustment/extension
• patent invalidity or design-around risk from known competitors
• the expected timing of generics and biosimilar-style entries (if applicable)

No patent family data, filing dates, or jurisdictional grant status is provided for “VIMSELTINIB,” so lifecycle-driven financial impact cannot be computed.

What would be the actionable investment metrics to track, if VIMSELTINIB’s commercial state were defined?

For a trackable commercial asset, the minimum set of investment metrics would be:

• indication-level approval date and label breadth
• net price (WAC vs. net), rebates/discounts, and payer coverage
• uptake curve by line of therapy and biomarker prevalence
• competitor launches and sequencing impact
• patent expiry and exclusivity end dates by geography

No such defined commercial state is available in the provided information.

Key takeaways

• VIMSELTINIB’s market dynamics and financial trajectory cannot be produced at an investment-grade level because the required, auditable inputs (approval status, indication, pricing, market size, and patent/lifecycle timeline) are not provided.
• Any attempt to generate forecasts or quantify competitive and pricing dynamics would not meet the standard for actionable business decisions.
• An evidence-based trajectory requires a verified mapping of VIMSELTINIB to an approved product, its indication, and its patent family and timeline.

FAQs

1. Is VIMSELTINIB approved and in active commercial use?
   Not determinable from the provided information.

2. What is VIMSELTINIB’s primary indication and line of therapy?
   Not determinable from the provided information.

3. What is VIMSELTINIB’s expected pricing and reimbursement path?
   Not determinable from the provided information.

4. What is VIMSELTINIB’s patent expiry landscape by geography?
   Not determinable from the provided information.

5. Can a revenue and cash-burn forecast be built for VIMSELTINIB?
   Not with the information provided.

References

[1] (No sources cited because no verifiable, asset-specific approval, pricing, market sizing, or patent data for “VIMSELTINIB” is present in the provided content.)